Future Science Group
Browse
Suppl_Fig_2.jpg (498.96 kB)

Real-world outcomes in patients with first-line and second-line therapy for advanced esophageal squamous cell carcinoma Suppl Fig 2

Download (498.96 kB)
figure
posted on 2023-05-15, 13:57 authored by Daniel Ahn, Michelle Sidel, Laura Panattoni, Naomi Sacks, Jennifer Hernandez, Reginald Villacorta

Real-world outcomes in patients with first-line and second-line therapy for advanced esophageal squamous cell carcinoma Suppl Fig 2 

Funding

This study was funded by Novartis Pharmaceuticals Corporation, which was involved in study design; in the collection, analysis and interpretation of data; in writing of the report; and in the decision to submit the article for publication. Employees from Novartis Pharmaceuticals Corporation participated as authors in publication, in compliance with authorship guidelines from the International Committee of Medical Journal Editors. All authors contributed to and approved the article. L Panattoni, N Sacks and J Hernandez received funding from Novartis Pharmaceuticals Corporation to conduct this research. R Villacorta and M Sidel were employees of Novartis Pharmaceutical Corporation when this research was conducted. D Ahn has received personal fees from Exelixis, Novartis, Genentech, Eisai, Daiichi Sankyo and Advanced Accelerator Applications. The authors have no other relevant affiliations or financial involvement with any organization or entity with a financial interest in or financial conflict with the subject matter or materials discussed in the manuscript apart from those disclosed.

History

Usage metrics

    Future Oncology

    Exports

    RefWorks
    BibTeX
    Ref. manager
    Endnote
    DataCite
    NLM
    DC